Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-
labeled PET agents has become increasingly important in recent years. Imaging of …

Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …

The Precision Medicine Initiative aims to use advances in basic and clinical research to
develop therapeutics that selectively target and kill cancer cells. Under the same doctrine of …